Combination of Tenofovir Disoproxil Fumarate and Peginterferon α-2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Patients chronically infected with the hepatitis B virus rarely achieve loss of serum hepatitis B surface antigen (HBsAg) with the standard of care. We evaluated HBsAg loss in patients receiving the combination of tenofovir disoproxil fumarate (TDF) and peginterferon α-2a (peginterferon) for a finite duration in a randomized trial.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Gastroenterology

Title: Gastroenterology

Publisher: Elsevier BV

ISSN (Electronic): 1528-0012

ISSN (Print): 0016-5085

Publication date (Electronic): Jan 2016

Volume: 150

Issue: 1

Affiliations

[1 ] Service d'Hépatologie, Hôpital Beaujon, University Paris-Diderot, Inserm Centre de Recherche sur l'Inflammation, Clichy, France.

[2 ] Division of Gastroenterology, Yonsei University College of Medicine, Seoul, South Korea.

[3 ] Drexel University College of Medicine, Philadelphia, Pennsylvania.

[4 ] National Institute for Infectious Diseases, "Matei Bals", Bucharest, Romania.

[5 ] Kyungpook National University Hospital, Daegu, South Korea.

[6 ] Toronto Liver Center, Toronto, Canada.

[7 ] Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.

[8 ] Yong Loo Lin School of Medicine, National University of Singapore, Singapore.

[9 ] University of Istanbul, Cerrahpasa Medical Faculty, Istanbul, Turkey.

[10 ] Liver Clinic, Surat, India.

[11 ] IFI Institute for Interdisciplinary Medicine at the Asklepios Klinik St. George, University of Hamburg, Hamburg, Germany.

[12 ] Queen Mary University of London, London, United Kingdom.

[13 ] Nexus Development, Palo Alto, California.

[14 ] Gilead Sciences Inc, Foster City, California.

[15 ] Academic Medical Center, Amsterdam, The Netherlands.

[16 ] University of Toronto, Department of Medicine, Toronto General Hospital, Toronto, Canada.

[17 ] AW Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital and University of Sydney, Sydney, Australia.

[18 ] San Jose Gastroenterology, San Jose, California.

[19 ] Hepatology Unit, Hospital Universitari Vall d'Hebron and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas del Instituto Carlos III, Barcelona, Spain.

[20 ] Viral Hepatitis Unit, Department of Clinical and Experimental Medicine, Second University of Naples, Naples, Italy.

[21 ] The Chinese University of Hong Kong, Alice Ho Miu Ling Nethersole Hospital, Hong Kong.

[22 ] Athens University Medical School, "Laiko" General Hospital of Athens, Athens, Greece.

[23 ] Department of Infectious Diseases and Hepatology, Medical University of Bialystok, Bialystok, Poland.

[24 ] Department of Medicine and Therapeutics and Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong. Electronic address: hlychan@cuhk.edu.hk.

Article

Publisher Item ID: S0016-5085(15)01429-8

DOI: 10.1053/j.gastro.2015.09.043

PubMed ID: 26453773

SO-VID: 8bd37722-74a2-4890-b081-d0d6f3a3ddab

History

Keywords: Clinical Trial,HBV,HBeAg Seroconversion,Virologic Response

Data availability:

Keywords: Clinical Trial, HBV, HBeAg Seroconversion, Virologic Response

Comments

Comment on this article

scite_

Cited by 108

See all cited by